Why the study?
Is prolonged out-of-hospital prophylaxis with low-molecular-weight heparin cost-effective in patients following total hip replacement?
Is prolonged out-of-hospital prophylaxis with low-molecular-weight heparin cost-effective in patients following total hip replacement?
Answers are grounded in this paper and cite their sources.
Prolonged out-of-hospital prophylaxis with LMWH after total hip replacement is cost-saving if administration costs are below 3,400 Swedish kronor per patient.
Several studies have demonstrated that prolongation of thromboprophylaxis after elective hip replacement significantly reduces the frequency of venographically demonstrated deep vein thrombosis. This paper reports an economic evaluation of prolonged prophylaxis with low-molecular-weight heparin (LMWH), based on outcome data from one of these trials. Analysis showed a net saving per patient of 3,400 Swedish kronor. Consequently, if the costs of administering the LMWH -- which includes the cost of teaching the patient to self-administer whilst in hospital and the cost of a follow-up visit by a district nurse to ensure compliance -- are below this amount, the intervention will prove to be cost saving.
No takes yet. Share an insight, caveat, or question.
Bergqvist et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: